Adecatumumab

Drug Profile

Adecatumumab

Alternative Names: Anti-EpCAM mAb MT201; Human anti-EpCAM monoclonal antibody MT201; Monoclonal antibody MT201; MT 201; MT201 antibody

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Micromet Inc
  • Developer Amgen; Merck Serono
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Epithelial cell adhesion molecule inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Prostate cancer
  • Discontinued Breast cancer; Colorectal cancer

Most Recent Events

  • 07 Mar 2012 Micromet Inc has been acquired by Amgen
  • 10 Nov 2011 Micromet completes a phase II trial in Colorectal cancer in France and Germany (NCT00866944)
  • 04 Oct 2010 Adecatumumab is still in phase I trials for Breast cancer (combination therapy) in Austria and Germany
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top